RNAi therapy for neurodegenerative diseases
- PMID: 16984810
- DOI: 10.1016/S0070-2153(06)75003-7
RNAi therapy for neurodegenerative diseases
Abstract
RNA interference (RNAi) mediates gene silencing in a sequence-specific manner and has proven to be an exceptionally valuable discovery for bench scientists. In the laboratory, RNAi technologies provide efficient means for validating drug targets and for performing reverse genetics to study gene function (Friedman and Perrimon, 2004). Patients may also benefit from RNAi as applications extend to potential human therapies. RNAi-based treatments are being investigated and may provide hope for patients suffering from cancer, viral infections, or genetic diseases for which effective therapies are currently lacking. Notably, several independent studies have demonstrated that RNAi therapy can improve disease phenotypes in various mouse models of human disease. In this chapter, we focus on the potential of RNAi in treating neurologic diseases for which reduction of mutant or toxic gene expression may provide therapeutic benefit. We discuss approaches to achieving RNAi in vivo, progress in the field, and the potential pitfalls associated with RNAi-based therapies.
Similar articles
-
RNAi therapeutics for CNS disorders.Brain Res. 2010 Jun 18;1338:112-21. doi: 10.1016/j.brainres.2010.03.038. Epub 2010 Mar 20. Brain Res. 2010. PMID: 20307511 Review.
-
RNA interference based gene therapy for neurological disease.Brief Funct Genomic Proteomic. 2007 Mar;6(1):40-9. doi: 10.1093/bfgp/elm005. Epub 2007 May 3. Brief Funct Genomic Proteomic. 2007. PMID: 17478451 Review.
-
Therapeutic RNA interference for neurodegenerative diseases: From promise to progress.Pharmacol Ther. 2007 Apr;114(1):34-55. doi: 10.1016/j.pharmthera.2007.01.003. Epub 2007 Jan 25. Pharmacol Ther. 2007. PMID: 17316816 Review.
-
[Therapeutic RNA interference for neurodegenerative diseases].Rev Neurol. 2008 Dec 16-31;47(12):641-7. Rev Neurol. 2008. PMID: 19085881 Review. Spanish.
-
Viral-based modelling and correction of neurodegenerative diseases by RNA interference.Gene Ther. 2006 Mar;13(6):487-95. doi: 10.1038/sj.gt.3302690. Gene Ther. 2006. PMID: 16319945 Review.
Cited by
-
Pressing diseases that represent promising targets for gene therapy.Discov Med. 2017 Dec;24(134):313-322. Discov Med. 2017. PMID: 29373809 Free PMC article. Review.
-
Ribonucleic acid interference induced gene knockdown.J Indian Soc Periodontol. 2013 Jul;17(4):417-22. doi: 10.4103/0972-124X.118309. J Indian Soc Periodontol. 2013. PMID: 24174717 Free PMC article. Review.
-
Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.Mol Ther. 2009 Sep;17(9):1563-73. doi: 10.1038/mt.2009.123. Epub 2009 Jun 16. Mol Ther. 2009. PMID: 19532137 Free PMC article.
-
Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.PLoS One. 2011;6(6):e21352. doi: 10.1371/journal.pone.0021352. Epub 2011 Jun 21. PLoS One. 2011. PMID: 21712955 Free PMC article.
-
Lentiviral delivery of short hairpin RNAs.Adv Drug Deliv Rev. 2009 Jul 25;61(9):732-45. doi: 10.1016/j.addr.2009.03.004. Epub 2009 Mar 31. Adv Drug Deliv Rev. 2009. PMID: 19341774 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical